Company Profile
Current handling and production of pluripotent cells and stem-cell derived lineages suffers from labor intensive manual culturing steps, frequent feeding of cultures, undefined matrices, inadequate purification, and other problems. These problems greatly increase time, costs, variability of results, scale-up difficulties and other barriers to industrial viability.
Primorigen is solving these problems by providing innovative solutions for stem cell maintenance, proliferation, characterization and assay development, including StemAdhere™, a recombinant human protein that offers a defined substrate for pluripotent cell proliferation, and its completely xenobiotic-free version StemAdhere™ XF (coming). Products in development include new defined matrices for stem cell differentiation, and a user-friendly, cost-effective system for large scale stem cell production. Primorigen also is developing human stem cell-derived disease models for high throughput, low cost compound and toxicity screening, addressing a strong need in pharmaceutical drug discovery.
In addition, Primorigen offers an integrated portfolio of products and technologies, including mouse mesenchymal stem cells and multiplexed protein assays to characterize cellular development and function in support of regenerative medicine therapeutics development.
Primorigen’s proprietary Spot on Dots™ frameless microarray platform provides a versatile, high-throughput substrate for building quantitative assays to detect proteins of interest. The platform offers greater speed and flexibility for antibody screening and assay development, and generates thousands of data points per experiment at a fraction of the costs of other systems, including ELISA, with fast, easy readouts and software that reports complex results within minutes.
| Pharmaceuticals |
|
Human Diagnostics |
|
| Med or Lab Devices |
|
Lab Reagents or Services |
 |
| Drug Manufacturing |
|
Food & Agribusiness |
|
| CRO |
|
Bioinformatics or Software |
|
| |
|
Other |
|
|
|
Primorigen has an alliance with and licensed its original cellular reprogramming technology IP from NuPotential LLC, a company based in Louisiana that was founded by Chuck Oehler and a former Infigen Inc. scientist, Dr. Eilertsen.
|